Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
More about this company
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Sector: health
Conviction from: NASDAQ
52-week range: 7.8730.99
2 tracked filer(s) hold this · 2 opened, 0 added, 0 trimmed in 30-SEP-2026
Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 68. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-03-02 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 11.5% | High | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-03-02 | RA CAPITAL MANAGEMENT, L.P. | director+10%-owner | 300,000 | $4,800,000 | Form 4 |